Corporate News
calendar
28 Dec, 2020
SHANGHAI, China, December 28, 2020 - Genor Biopharma Co Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing immune-oncology therapeutics, announced today that multiple IND applications of GB491 (cyclin-dependent kinase 4/6 inhibitor) are under review by NMPA, including indications for 1L/2L hormone receptor positive / human epidermal growth factor receptor 2 negative (HR+/HER2-) locally advanced or metastatic breast cancer.
1687
calendar
04 Nov, 2020
SHANGHAI, China, Nov 4, 2020 -- Genor Biopharma Co. Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing immune-oncology therapeutics, announced that its New Drug Application (NDA) for its infliximab biosimilar GB242 to National Medical Products Administration (NMPA) is under review. Genor submitted NDA on October 27 2020 and NMPA accepted on the NDA on November 3 2020, which again demonstrated strong execution capabilities of Genor team.
1684
calendar
27 Oct, 2020
SHANGHAI, China, Oct. 27, 2020 -- Genor Biopharma Co. Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing immune-oncology therapeutics, announced today that it has submitted New Drug Application (NDA) for its infliximab biosimilar GB242 to National Medical Products Administration (NMPA).
1681
calendar
07 Oct, 2020
JHBP (CY) Holdings Limited (“Genor Biopharma” or the “Company”; stock code: 6998.HK), a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs, was successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”) at 9:00am today, with a board lot of 500 Shares each.
1678
calendar
05 Aug, 2020
SHANGHAI, China, August 5, 2020 -- Genor Biopharma Co. Inc announced that National Medical Products Administration (NMPA) has granted priority review status to its new drug application (NDA) for Geptanolimab, a PD-1 mAb, on July 28, 7 days after the NDA acceptance.
1653